Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-GT™
HUGO-Ab™
Humanized Target Gene Models
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Transgenic Model Generation
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Drug Discovery and Development
Antibody Discovery Platform
HUGO-Ab™
HUGO-Mab™
HUGO-Light™
HUGO-Nano™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Neuropathic Pain
Metabolic & Cardiovascular
Obesity
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Innovative Drug R&D
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
Bispecific Antibodies (BsAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Fully Human Antibody Library
Neurology Antibodies
Metabolic & Cardiovascular Antibodies
Ophthalmology Antibodies
Oncology Antibodies
Immunology & Inflammation Antibodies
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Corporate Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login
HomeMouseAtlas
C57BL/6JCya-Dclre1cem1/Cya
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Catalog Type
Product Name
Main Area of Research
How did you hear about us?
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.

C57BL/6JCya-Dclre1cem1/Cya

Common Name
Dclre1c-KO
Product ID
S-KO-16327
Backgroud
C57BL/6JCya
Strain ID
KOCMP-227525-Dclre1c-B6J-VB
Status
Research and Development
When using this mouse strain in a publication, please cite “Dclre1c-KO Mouse (Catalog S-KO-16327) were purchased from Cyagen.”
KO Models
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
+
KO Models
Basic Information
Strain Name
Dclre1c-KO
Strain ID
KOCMP-227525-Dclre1c-B6J-VB
Gene Name
Dclre1c
Product ID
S-KO-16327
Gene Alias
Art, Snm1l, 9930121L06Rik
Background
C57BL/6JCya
Gene Full Name
DNA cross-link repair 1C
Modification
Conventional knockout
NCBI ID
227525 (Mouse)
Phenotype
MGI:2441769
Chromosome
Chr 2 (Mouse)
Application
--
Datasheet
Click here to download >>
More
Rare Disease Data Center >>
Strain Description
Ensembl Transcript ID
ENSMUST00000102988
NCBI Transcript ID
NM_146114
Target Region
Exon 4~12
Size of Effective Region
~15.5 kb
Overview of Gene Research
Dclre1c, also known as the gene encoding Artemis, is crucial for V(D)J recombination, an essential process in the differentiation and maturation of T and B cells. It is also involved in the repair of DNA double-strand breaks via the non-homologous end-joining (NHEJ) pathway [4,5,6,7].

In a phase 1-2 clinical study, lentiviral gene therapy using autologous CD34+ cells transfected with DCLRE1C was carried out in infants with Artemis-deficient severe combined immunodeficiency (ART-SCID). The therapy led to genetically corrected and functional T and B cells [1]. NK cells from DCLRE1C-deficient severe combined immunodeficiency (SCID) patients were found to be functional in inhibiting HCMV transmission between cells in vitro [2]. Dclre1c-deficient mice with an NOD genetic background, generated using CRISPR/Cas9-mediated gene editing, exhibited a radiosensitive SCID phenotype with reduced T and B lymphocyte populations and were successfully engrafted with cell lines and patient-derived tumor xenografts [3].

In conclusion, Dclre1c is essential for V(D)J recombination and DNA repair, playing a key role in the development and function of the immune system. The study of Dclre1c-deficient mouse models and human patient-based research has provided insights into its role in immunodeficiency diseases, such as ART-SCID, and has potential implications for gene therapy and understanding immune-related disorders [1,2,3].

References:
1. Cowan, Morton J, Yu, Jason, Facchino, Janelle, McIvor, R Scott, Puck, Jennifer M. . Lentiviral Gene Therapy for Artemis-Deficient SCID. In The New England journal of medicine, 387, 2344-2355. doi:10.1056/NEJMoa2206575. https://pubmed.ncbi.nlm.nih.gov/36546626/
2. Wu, Zeguang, Subramanian, Narmadha, Jacobsen, Eva-Maria, Hönig, Manfred, Mertens, Thomas. 2019. NK Cells from RAG- or DCLRE1C-Deficient Patients Inhibit HCMV. In Microorganisms, 7, . doi:10.3390/microorganisms7110546. https://pubmed.ncbi.nlm.nih.gov/31717670/
3. Bin, Yixiao, Wei, Sanhua, Chen, Ruo, Chen, Zhinan, Zhang, Hai. 2024. Dclre1c-Mutation-Induced Immunocompromised Mice Are a Novel Model for Human Xenograft Research. In Biomolecules, 14, . doi:10.3390/biom14020180. https://pubmed.ncbi.nlm.nih.gov/38397417/
4. Mou, Wenjun, Gao, Liwei, He, Jianxin, Xu, Baoping, Gui, Jingang. 2021. Compound heterozygous DCLRE1C mutations lead to clinically typical Severe Combined Immunodeficiency presenting with Graft Versus Host Disease. In Immunogenetics, 73, 425-434. doi:10.1007/s00251-021-01219-4. https://pubmed.ncbi.nlm.nih.gov/34406419/
5. Watanabe, Go, Lieber, Michael R, Williams, Dewight R. . Structural analysis of the basal state of the Artemis:DNA-PKcs complex. In Nucleic acids research, 50, 7697-7720. doi:10.1093/nar/gkac564. https://pubmed.ncbi.nlm.nih.gov/35801871/
6. Volk, Timo, Pannicke, Ulrich, Reisli, Ismail, Schwarz, Klaus, Grimbacher, Bodo. 2015. DCLRE1C (ARTEMIS) mutations causing phenotypes ranging from atypical severe combined immunodeficiency to mere antibody deficiency. In Human molecular genetics, 24, 7361-72. doi:10.1093/hmg/ddv437. https://pubmed.ncbi.nlm.nih.gov/26476407/
7. Pannicke, Ulrich, Hönig, Manfred, Schulze, Ilka, Friedrich, Wilhelm, Schwarz, Klaus. . The most frequent DCLRE1C (ARTEMIS) mutations are based on homologous recombination events. In Human mutation, 31, 197-207. doi:10.1002/humu.21168. https://pubmed.ncbi.nlm.nih.gov/19953608/
Quality Control Standard
Sperm Test

Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.

Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.

Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Inquiry Details
Main Area of Research
Service(s) of Interest
Gene of Interest
Project Details
How did you hear about us?
Contact Information
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCorporate OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
Key Insights
The industry is undergoing a rapid transformation driven by next-generation modalities, globalized markets, and upstream technological innovations.
  • Market Structural Shift: Monoclonal antibodies drive steady growth, but ADCs and bispecifics are rapidly accelerating, reshaping the market with higher-value innovations.
  • Chinese Market Globalization: China is actively expanding globally, evidenced by a surge in high-value cross-border license-out deals.
  • Technology-Driven Efficiency: Advanced discovery engines—exemplified by Cyagen's HUGO-Ab platform and AI algorithms—are streamlining candidate screening, optimizing molecular design, and localizing the upstream supply chain.
  • Oncology-Focused Innovation: R&D pipelines remain heavily concentrated on high-incidence malignancies like non-small cell lung cancer, utilizing complex modalities to combat clinical resistance.
Now Available for Download
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research